Results of isolated lower limb perfusion for loco-regional advanced/recurrent melanoma using borderline true hyperthermia plus additional bolus of melphalan. A critical analysis of homogeneous cases

Journal of Surgical Oncology

Volumn 104, Issue 7, 2011, Pages 718-723

  Pace, Marcello ^a   Gattai, Riccardo ^a   Mascitelli, Erminia M ^a   Millanta, Luigi ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

borderline true hyperthermia; clinical results; limb perfusion; melanoma; melphalan

Indexed keywords

DACTINOMYCIN; MELPHALAN;

ACUTE TOXICITY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLISTER; BORDERLINE TRUE HYPERTHERMIA; CANCER STAGING; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISTANT METASTASIS; EDEMA; ERYTHEMA; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; HYPERTHERMIC THERAPY; ISOLATED LOWER LIMB PERFUSION; LIMB PERFUSION; LOWER LIMB MELANOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; NERVE PARALYSIS; PATIENT SAFETY; PRIORITY JOURNAL; RECURRENT DISEASE; RETROPERITONEAL HEMORRHAGE; SURVIVAL RATE; THERAPY EFFECT; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTHERMIA, INDUCED; LEG; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 80255124884     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21949     Document Type: Article

References (47)

1. Pace M,: Optimization of the vascular isolation in isolated regional perfusion of the limbs. Reg Cancer Treat 1990; 3: 90-97. (Pubitemid 20360549)
2. Lazzerini S, Millanta L, Olmi R, et al.: An analysis of heat supply and temperature distribution in isolated hyperthermic perfusion of the limbs. Phys Med 1991; 7: 135-143.
3. Pace M, Millanta L, Bellacci M, et al.: Heat administration temperature monitoring and control in hyperthermic-antibalstic perfusion of the limbs. Reg Cancer Treat 1992; 4: 207-212. (Pubitemid 23076988)
4. Pace M, Millanta L, Gattai R, et al.: Optimal procedure for thermal delivery in hyperthermic/chemotherapeutic treatments in the isolated perfusion of the limbs. J Exp Clin Cancer Res 2005; 24: 35-42. (Pubitemid 40655860)
5. Pace M, Millanta L, Gattai R, et al.: Key factors for best control of the systemic leakage during hyperthermic isolated limb perfusion (HILP) in ECC. A critical synthesis of our experience. J Exp Clin Cancer Res 2007; 26: 433-442. (Pubitemid 351175602)
6. Pace M, Gattai R, Matteini M, et al.: Toxicity and morbility after isolated lower limb perfusion in 242 chemo-hyperthermal treatments for cutaneous melanoma: The experience of the Tuscan Reference Centre. J Exp Clin Cancer Res 2008; 27: 67.
7. Schraffordt Koops H,: Prevention of neural and muscular lesions during hyperthermic regional perfusion. Surg Gynecol Obstet 1972; 135: 401-403.
8. Kroon BBR, Klase JM, van Geel AN, et al.: Application of hyperthermia in regional isolated perfusion for melanoma of the limbs. Reg Cancer Treat 1992; 4: 223-226. (Pubitemid 23076992)
9. Vrouenraets BC, Eggermont AM, Klaase JM, et al.: Long-term neuropathy after regional isolated perfusion with melphalan for melanoma of the limbs. Eur J Surg Oncol 1994; 20: 681-685.
10. Pace M, Galli A, Bellacci A,: True hyperthermia plus double melphalan bolus in the isolated perfusion for stage III lower limb melanoma. A pilot study. Reg Cancer Treat 1996; 9: 1-7. (Pubitemid 26360193)
11. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization; 1979.
12. Kaplan EL, Meier P,: Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958; 53: 457-481.
13. Wieberdink J, Benckhuijsen C, Braat RP, et al.: Dosimetry in isolated perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clinic Oncol 1982; 18: 905-910. (Pubitemid 13147887)
14. Miller AB, Hoogstratem B, Staquet M,: Reporting results of cancer treatment. Cancer 1981; 47: 207-214. (Pubitemid 11167383)
15. Klaase JM, Kroon BB, van Geel BN, et al.: Patient- and treatment-related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities. Am J Surg 1994; 167: 618-620. (Pubitemid 24332525)
16. Thompson JF, Lai DT, Ingvar C, et al.: Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Melanoma Res 1994; 1: 45-50. (Pubitemid 24144674)
17. Vrouenraets BC, Klaase JM, Kroon BB, et al.: Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. Arch Surg 1995; 130: 43-47.
18. Noorda EM, Vrouenraets BC, Nieweg OE, et al.: Long-term results of a double perfusion schedule using high dose hyperthermia and melphalan sequentially in extensive melanoma of the lower limb. Melanoma Res 2003; 13: 395-399. (Pubitemid 36900702)
19. Noorda EM, Vrouenraets BC, Nieweg OE, et al.: Prognostic factors for survival after isolated limb perfusion for malignant melanoma. Eur J Surg Oncol 2003; 29: 916-921. (Pubitemid 37493294)
20. Knorr C, Meyer T, Janssen T, et al.: Hyperthermic isolated limb perfusion (HILP) in malignant melanoma. Experience with 101 patients. Eur J Surg Oncol 2006; 32: 224-227. (Pubitemid 43257128)
21. Storm FK, Morton DL,: Value of therapeutic hyperthermic limb perfusion in advanced recurrent melanoma of the lower extremity. Am J Surg 1985; 150: 32-35. (Pubitemid 15071744)
22. Di Filippo F, Calabrò A, Giannarelli D, et al.: Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer 1989; 63: 2551-2561. (Pubitemid 19152772)
23. Skene AI, Bulman AS, Williams TR, et al.: Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb. Br J Surg 1990; 77: 765-767. (Pubitemid 20236115)
24. Kroon BBR, Klasse JM, van Geel BN, et al.: Application of hyperthermia in regional isolated perfusion for melanoma of the limbs. Reg Cancer Treat 1992; 4: 223-226. (Pubitemid 23076992)
25. Vrouenraets BC, Nieweg OE, Kroon BB,: Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg 1996; 83: 1319-1328. (Pubitemid 26342147)
26. Liénard D, Eggermont AM, Koops HS, et al.: Isolated limb perfusion with tumor necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999; 9: 491-502. (Pubitemid 29494115)
27. Noorda EM, Takkenberg B, Vrouenraets BC, et al.: Isolated limb perfusion prolongs the limb recurrence-free interval after several episodes of excisional surgery for locoregional recurrent melanoma. Ann Surg Oncol 2004; 11: 491-499. (Pubitemid 40486730)
28. Hafstrom L, Jonsson PE,: Hyperthermic perfusion of recurrent malignant melanoma on the extremities. Acta Chir Scand 1980; 146: 313-318. (Pubitemid 11226375)
29. Abdel-Wahab OI, Grubbs E, Viglianti BL, et al.: The role of hyperthermia in regional alkylating agent chemotherapy. Clin Cancer Res 2004; 10: 5919-5929. (Pubitemid 39180974)
30. Aloia TA, Grubbs E, Onaitis M, et al.: Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response. Arch Surg 2005; 140: 1115-1120. (Pubitemid 41668683)
31. Vaglini M, Santinami M, Manzi R, et al.: Treatment of in-transit metastases from cutaneous melanoma by isolation perfusion with tumour necrosis factor-alpha (TNF-alpha), melphalan and interferon-gamma (IFN-gamma). Dose-finding experience at the National Cancer Institute of Milan. Melanoma Res 1994; 4: 35-38. (Pubitemid 24144672)
32. Klop WM, Vrouenraets BC, van Geel BN, et al.: Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs. J Am Coll Surg 1996; 182: 467-472. (Pubitemid 26176477)
33. Eggermont AMM,: Treatment of melanoma in transit metastasis confined to limb. Cancer Surv 1996; 26: 335-349. (Pubitemid 126734884)
34. Fraker D, Alexander H, Ross M, et al.: A phase III trial of isolated limb perfusion for extremity melanoma comparing melphalan alone versus melphalan plus tumor necrosis factor (TNF) plus interferon gamma. Ann Surg Oncol 2002; 9: S8.
35. Eggermont AMM, Brunstein F, Grünhagen D, et al.: Regional treatment of metastasis: role of regional perfusion. State of the art isolated limb perfusion for limb salvage. Ann Oncol 2004; 15: iv107-iv112. (Pubitemid 39585321)
36. Noorda EM, Vrouenraets BC, Nieweg OE, et al.: Repeat isolated limb perfusion with TNF-alpha and melphalan for recurrent limb melanoma after failure of previous perfusion. Eur J Surg Oncol 2006; 32: 318-324.
37. Di Filippo F, Giacomini P, Rossi CR, et al.: Prognostic factors influencing tumor response, locoregional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb perfusion. In Vivo 2009; 23: 347-352.
38. Cornett WR, McCall LM, Petersen RP, et al.: Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 2006; 24: 4196-4201. (Pubitemid 46622299)
39. Moreno-Ramírez D, de la Cruz L, Ferrándiz L, et al.: Study and treatment of locally advanced melanoma. Actas Dermosifiliogr 2009; 100: 767-779.
40. Padsis J, Turley R, Tyler D,: Pharmacotherapy of regional melanoma therapy. Expert Opin Pharmacother 2010; 11: 79-93.
41. Hafstrom L, Rudenstam CM, Blomquist E, et al.: Regional hyperthermic perfusion with melphalan after surgery for recurrence malignant melanoma of the extremities. Swedish Melanoma Study Group. J Clin Oncol 1991; 9: 2091-2094.
42. Feldman AL, Alexander HR Jr, Bartlett DL, et al.: Management of extremity recurrences after complete responses to isolated limb perfusion in patients with melanoma. Ann Surg Oncol 1999; 6: 562-567. (Pubitemid 29428795)
43. Rossi CR, Foletto M, Pilati P, et al.: Isolated limb perfusion in locally advanced cutaneous melanoma. Semin Oncol 2002; 29: 400-409. (Pubitemid 34857888)
44. Klaase JM, Kroon BB, van Geel AN, et al.: Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery 1994; 115: 39-45. (Pubitemid 24039210)
45. Thompson JF, Hunt JA, Shannon KF, et al.: Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg 1997; 132: 903-907. (Pubitemid 27344144)
46. Krementz ET, Sutherland CM, Muchmore JH,: Isolated hyperthermia chemotherapy perfusion for limb melanoma. Surg Clin North Am 1996; 76: 1313-1330. (Pubitemid 27010039)
47. Balch CM, Buzaid AC, Soong SJ, et al.: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-3648. (Pubitemid 32786276)